# US 2021/0341448 A1 · Screening method for therapeutic drug or prophylactic drug for tauopathy and diagnostic method for tauopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341448 A1
- Document ID: US20210341448A1
- Status: Published application
- Kind: A1
- Application number: 17/284,220
- Filed: 2019-10-31
- Published: 2021-11-04
- Earliest claimed: 2018-11-01
- Assignees: National Center for Geriatrics and Gerontology
- Applicants: National Center for Geriatrics and Gerontology
- Inventors: Akiyoshi KAWAI; Tetsuya KIMURA; Hasi HUHE
- Web page: https://patentgrep.com/patent/US20210341448A1

## CPC

- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility}
- C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- G01N 33/5058: {Neurological cells}
- G01N 33/5436: {with ligand physically entrapped within the solid phase (liposomes G01N33/5432; immunological test elements G01N33/54386)}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2333/70571: for neuromediators, e.g. serotonin receptor, dopamine receptor
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is a screening method for an agent for treating or preventing tauopathy, the method comprising (1) a step of contacting an NMDA-type glutamate receptor with a tau oligomer in the presence or absence of a candidate compound, and (2) a step of evaluating a direct binding of the tau oligomer to the NMDA-type glutamate receptor. Further provided is a test method for tauopathy, the method comprising (1) a step of contacting an NMDA-type glutamate receptor with a sample isolated from a subject, and (2) a step of quantifying tau oligomers directly binding to the NMDA-type glutamate receptor.

## Claims

### Claim 1

A screening method for an agent for treating or preventing tauopathy, comprising:
(1) a step of contacting an NMDA-type glutamate receptor with a tau oligomer in the presence or absence of a candidate compound, and
(2) a step of evaluating a direct binding of the tau oligomer to the NMDA-type glutamate receptor.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the NMDA-type glutamate receptor is isolated from a cell membrane or a liposomal membrane while the NMDA-type glutamate receptor maintains a quaternary structure.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the NMDA-type glutamate receptor is contained on a cell membrane or a liposomal membrane while the NMDA-type glutamate receptor maintains a physiological function.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the tau oligomer or the NMDA-type glutamate receptor is immobilized on a solid support.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the step (2) is carried out by ELISA, a protein array, or a surface plasmon resonance analysis.

### Claim 6 (depends on 3)

The method according to claim 3, further comprising (3) a step of measuring a calcium influx through the NMDA-type glutamate receptor into a cell or a liposome.

### Claim 7 (depends on 3)

The method according to claim 3, further comprising (4) a step of measuring incorporation of a membrane protein into a cell or a liposome.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the tau oligomer consists of 2 to 40 tau proteins.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the tau oligomer consists of 3 to 20 tau proteins.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the tau oligomer comprises a tau protein as a structural component, the tau protein comprising a phosphorylated amino acid in the C-terminal region downstream of an amino acid corresponding to the 373 position numbered according to the 2N4R isoform.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the tau oligomer comprises a tau protein as a structural component, the tau protein comprising in which serine corresponding to the 409, 412, 413 and/or 416 position numbered according to the 2N4R isoform is phosphorylated.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the tauopathy is Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, Pick's disease, argyrophilic grain dementia, multiple system tauopathy with presenile dementia (MSTD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), dementia with neurofibrillary tangles, diffuse neurofibrillary tangles with calcification (DNTC), white matter tauopathy with globular glial inclusions (WMT-GGI), or frontotemporal lobar degeneration with tau-positive inclusions (FTLD-tau).

### Claim 13

A test method for tauopathy, comprising:
(1) a step of contacting an NMDA-type glutamate receptor with a sample isolated from a subject, and
(2) a step of quantifying tau oligomers directly binding to the NMDA-type glutamate receptor.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the NMDA-type glutamate receptor is isolated from a cell membrane or a liposomal membrane while the NMDA-type glutamate receptor maintains a quaternary structure.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the NMDA-type glutamate receptor is contained on a cell membrane or a liposomal membrane while the NMDA-type glutamate receptor maintains a physiological function.

### Claim 16 (depends on 13)

The method according to claim 13, wherein the tau oligomer or the NMDA-type glutamate receptor is immobilized on a solid support.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the step (2) is carried out by ELISA, a protein array, or a surface plasmon resonance analysis.

### Claim 18 (depends on 15)

The method according to claim 15, further comprising (3) a step of measuring a calcium influx through the NMDA-type glutamate receptor into a cell or a liposome.

### Claim 19 (depends on 15)

The method according to claim 15, further comprising (4) a step of measuring incorporation of a membrane protein into a cell or a liposome.

### Claim 20 (depends on 13)

The method according to claim 13, wherein the tau oligomer consists of 2 to 40 tau proteins.

### Claim 21 (depends on 13)

The method according to claim 13, wherein the tau oligomer consists of 3 to 20 tau proteins.

### Claim 22 (depends on 13)

The method according to claim 13, wherein the tau oligomer comprises a tau protein as a structural component, the tau protein comprising a phosphorylated amino acid in the C-terminal region downstream of an amino acid corresponding to the 373 position numbered according to the 2N4R isoform.

### Claim 23 (depends on 13)

The method according to claim 13, wherein the tau oligomer comprises a tau protein as a structural component, the tau protein comprising in which serine corresponding to the 409, 412, 413 and/or 416 position numbered according to the 2N4R isoform is phosphorylated.

### Claim 24 (depends on 13)

The method according to claim 13, wherein the tauopathy is Alzheimer's disease, corticobasal degeneration, progressive supranuclear palsy, Pick's disease, argyrophilic grain dementia, multiple system tauopathy with presenile dementia (MSTD), frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), dementia with neurofibrillary tangles, diffuse neurofibrillary tangles with calcification (DNTC), white matter tauopathy with globular glial inclusions (WMT-GGI), or frontotemporal lobar degeneration with tau-positive inclusions (FTLD-tau).
